BNTX Ends BNT122 CRC Vaccine Trial After Survival Imbalance

BioNTech is terminating the Phase 2 BNT122-01 trial of autogene cevumeran, its individualized neoantigen mRNA cancer vaccine, in resected colorectal cancer. An independent data safety monitoring board identified a numerical imbalance in overall survival between treatment arms and concluded that continuing the study was unlikely to change the efficacy outcome. The stock closed at $111.40.

Autogene cevumeran is a personalized vaccine: each patient’s tumor is sequenced, and the mRNA is built to encode up to 20 neoantigens unique to that tumor, training the immune system to attack residual cancer cells. It is developed with Genentech/Roche and sits at the center of BioNTech’s iNeST platform. The colorectal program enrolled patients whose blood showed circulating tumor DNA, a marker of microscopic disease left behind after surgery, the exact setting where an adjuvant cancer vaccine is meant to earn its keep.

The trial (NCT04486378) tested the therapy as adjuvant monotherapy in patients with ctDNA-positive, surgically resected Stage II or Stage III colorectal cancer. The board’s language matters: this is a futility stop, not a safety signal. The DSMB did not flag a safety problem; it said more follow-up would not rescue the efficacy readout. In a futility stop, the treatment is not shown to be harmful, only that it is unlikely to beat the control arm on the outcome that matters most.

The setback is real but bounded. It is a Phase 2 miss in one adjuvant indication, not a registrational failure, and BioNTech’s broader autogene cevumeran program in pancreatic cancer and melanoma continues. For BioNTech investors, the oncology thesis has already shifted away from the CRC setting, anchored instead on pumitamig, its PD-1/VEGF bispecific, and BNT111, its FixVac melanoma program.

The readout also lands at an awkward moment for the category. Moderna and Merck’s intismeran cleared a Phase 3 melanoma trial on August 19, sending Moderna shares up sharply, and suggesting individualized neoantigen vaccines work in one disease while BioNTech’s version stumbled in another. The two are different designs tested in different tumors, so a direct read-across is unfair, but the contrast sharpens the question of where these vaccines actually hold up. For BioNTech, the iNeST platform was already a secondary leg to the mRNA infectious-disease franchise that made the company’s name during the pandemic.

What to watch next: whether BioNTech’s pancreatic cancer program, the most advanced remaining autogene cevumeran effort, delivers a signal strong enough to keep the platform narrative alive. Here is the intismeran win that reset expectations, and the three cancer-vaccine platforms competing for the same prize.

Source: BioNTech statement